ArticleExpert review of anticancer therapy2011
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer.
Article in Expert review of anticancer therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- A bibliometric analysis of nucleic acid probe and its applications in oncology: towards more precise molecular medicine.Discover oncology · 2025Review
- The Protective Role of Exosome-Derived MicroRNAs and Proteins from Human Breast Milk against Infectious Agents.Metabolites · 2023Article
- Single-Exosome Profiling Identifies ITGB3+ and ITGAM+ Exosome Subpopulations as Promising Early Diagnostic Biomarkers and Therapeutic Targets for Colorectal Cancer.Research (Washington, D.C.) · 2023Article
- Ultrathin Covalent Organic Framework Nanosheets/TiMolecules (Basel, Switzerland) · 2022Article
- Untargeted Metabolomic Profile for the Detection of Prostate Carcinoma-Preliminary Results from PARAFAC2 and PLS-DA Models.Molecules (Basel, Switzerland) · 2019Article
- Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop.Journal of extracellular vesicles · 2019Article
- Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas.Journal of Cancer · 2019Article
- Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management.Frontiers in oncology · 2018Review
- Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.Oncotarget · 2017Review
- Isolation and Profiling of MicroRNA-containing Exosomes from Human Bile.Journal of visualized experiments : JoVE · 2016Article
- BMP-regulated exosomes from Drosophila male reproductive glands reprogram female behavior.The Journal of cell biology · 2014Article
- Characterization of human plasma-derived exosomal RNAs by deep sequencing.BMC genomics · 2013Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is the most prevalent cancer in men over the age of 50 years. Prostate-specific antigen is limited as both an early detection and prognostic biomarker. Prostasomes are unique microvesicles of endocytic origin with a unique lamellar membrane composed of cholesterol and phospholipids known to be capable of fusing with other cells and thus acting as messengers between cells. The evaluated article presents a new highly sensitive and specific protein-targeted assay based upon a proximity ligation assay (PLA) deemed capable of detecting prostasomes in the blood plasma of men with prostate cancer. The 4-PLA assay was used to detect circulating prostasomes in men with prostate cancer compared with age-matched controls. The median prostatsome levels in blood plasma were 2.5- to seven-fold higher compared with controls. The blood plasma prostasome levels correlated with Gleason 7 and higher disease versus Gleason 6 or lower and controls. This study describes for the first time a highly sensitive assay that depends upon simultaneous binding to as many as five different epitopes for detection and is thus a new and powerful tool for biomarker identification and validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.